Gene therapy of thyroid cancer via retrovirally-driven combined expression of human interleukin-2 and herpes simplex virus thymidine kinase |
|
Genetic alterations in medullary thyroid cancer: diagnostic and prognostic markers |
|
Growth hormone deficiency in the transition period: body composition and gonad function. |
|
GSTM1 and CYP2D6 genotype frequencies in patients with pituitary tumours: effects on P53, ras and gsp. |
|
Guida pratica di endocrinologia / Marco Boscaro ; Decio Armanini ... [et al.] ; presentazione di Paolo Vitti e Andrea Giustina |
|
Harmful effects of functional hypercortisolism: a working hypothesis. |
|
High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. |
|
Hormonal responses during various phases of autoimmune adrenal failure: no evidence for 21-hydroxylase enzyme activity inhibition in vivo |
|
Human leucocytes in asthenozoospermic patients: endothelial nitric oxide synthase expression. |
|
Hypogonadism and reduced bone mineral density in heterozygous H63D mutation in the HFE gene: an unusual presentation of hereditary hemochromatosis |
|
In situ analysis of human menin in normal and neoplastic pancreatic tissues: evidence for differential expression in exocrine and endocrine cells |
|
In vitro metabolism of cortisol by human abdominal adipose tissue |
|
Incidentally discovered adrenal tumors: endocrine and scintigraphic correlates |
|
Increased factor VIII/vWf levels in patients with reduced platelet number. |
|
Inhibition of pituitary beta-endorphin by ACTH and glucocorticoids. |
|
Inhibitory effect of somatostatin on the aldosterone response to angiotensin II: in vitro studies |
|
Intrapituitary cytokines in Cushing's disease: do they play a role? |
|
Investigation of N-cadherin/β-catenin expression in adrenocortical tumors. |
|
Iperprolattinemia & adenomi ipofisari : attuali orientamenti terapeutici : Padova, 4 aprile 1997 / a cura di M. Boscaro, A. Paoletta, M. Scanarini |
|
Isolation and characterization of progenitor mesenchymal cells in human pituitary tumors |
|
Life events and neurocirculatory asthenia. A controlled study |
|
Life events in the pathogenesis of hyperprolactinemia |
|
Lipoproteins obtained from anorexia nervosa patients induce higher oxidative stress in U373MG astrocytes through nitric oxide production. |
|
Long-term glucocorticoid effect on bone mineral density in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. |
|
Low-dose ketoconazole treatment in hirsute women |
|
Management of primary aldosteronism: its complications and their outcomes after treatment |
|
Mitogen-Activated Protein Kinase Pathway: Genetic Analysis of 95 Adrenocortical Tumors |
|
Modulation of retrovirally driven therapeutic genes by mutant TP53 in anaplastic thyroid carcinoma. |
|
Molecular genetic studies of sporadic pituitary tumors |
|
Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes |
|
New aspects of mineralocorticoid hypertension |
|
New insight into the hypercoagulability of Cushing's syndrome |
|
Oleoylethanolamide protects human sperm cells from oxidation stress: studies on cases of idiopathic infertility. |
|
Paclitaxel is an effective antiproliferative agent on the human NCI-H295 adrenocortical carcinoma cell line |
|
Pathophysiology of dyslipidemia in Cushing's syndrome |
|
Patterns of ACTH response to oCRH in Cushing's disease: correlation with histological/immunocytochemical findings. |
|
Percutaneous therapy of varicocele: effects on semen parameters in young adults |
|
Perioperative thromboprophylaxis in Cushing's disease: What we did and what we are doing? |
|
Personality characteristics and quality of life in patients treated for Cushing's syndrome |
|
Pharmacologic management of Cushing syndrome : new targets for therapy. |
|
Pituitary microadenomas: surgical results and morphological findings |
|
Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. |
|
Plasma renin activity and urinary aldosterone in acromegaly |
|
Possible efficacy of Lavender and Tea tree oils in the treatment of young women affected by mild idiopathic hirsutism. |
|
Potential therapeutic effects of ritanserin in Cushing's disease |
|
Primary adrenal hypercortisolism: minimally invasive surgical treatment or medical therapy? A retrospective study with long-term follow-up evaluation. |
|
Pro-gamma-MSH levels in various disorders of pituitary-adrenal axis |
|
The production of peroxynitrite by human spermatozoa may affect sperm motility through the formation of protein nitrotyrosine |
|
Progesterone increase counteracts aldosterone action in a pregnant woman with primary aldosteronism |
|
Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas |
|
Protective effect of leg fat against cardiovascular risk factors in obese premenopausal women. |
|
Psychological distress and quality of life in endocrine disease. |
|
Psychosocial impairment in patients treated for pituitary disease: a controlled study. |
|
Quality of life of hirsute women |
|
Raloxifene and cardiovascular health: its relationship to lipid and glucose metabolism, hemostatic and inflammation factors and cardiovascular function in postmenopausal women. |
|
Reduced expression of the growth hormone and type 1 insulin-like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor. |
|
Reduced nitric oxide levels in acromegaly: cardiovascular implications. |
|
Regression of cardiac abnormalities after replacement therapy in Addison's disease |
|
Risk factors and long-term follow-up of adrenal incidentalomas |
|
The role of an acute pasireotide suppression test in predicting response to treatment in patients with Cushing's disease: findings from a pilot study |
|
Role of bilateral adrenalectomy in Cushing's disease |
|
The role of psychological well-being in obese and overweight older adults. |
|
Role of raloxifene on platelet metabolism and plasma lipids. |
|
Screening Tests for Cushing's Syndrome: Urinary Free Cortisol Role Measured by LC-MS/MS. |
|
Selective venous sampling in the differential diagnosis of ACTH-dependent Cushing's syndrome |
|
Serum levels of calcitonin in Cushing's syndrome |
|
Sexual symptoms in endocrine diseases: psychosomatic perspectives |
|
Slow-release lanreotide treatment in acromegaly: effects on quality of life. |
|
Small tumor size as favorable prognostic factor after adrenalectomy in Conn's adenoma. |
|
Spironolactone and intermenstrual bleeding in polycystic ovary syndrome with normal BMI. |
|
Steroids and hypertension. |
|
Synergistic antitumour activity of RAF265 and ZSTK474 on human TT medullary thyroid cancer cells |
|
Systematic review of surgical treatment of subclinical Cushing's syndrome. |
|
Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center |
|
Therapy of endocrine disease: outcomes in patients with Cushing's disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence. |
|
Transcriptionally targeted retroviral vector for combined suicide and immunomodulating gene therapy of thyroid cancer |
|
Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. |
|
Type I and type II disease in congenital factor XIII deficiency. A further demonstration of the correctness of the classification |
|
Up-to 5-year efficacy of pasireotide in a patient with Cushing's disease and pre-existing diabetes: literature review and clinical practice considerations. |
|
Use of the desmopressin test in the differential diagnosis of pseudo-Cushing state from Cushing's disease. |
|
Vascular endothelial growth factor and microvessel density in periodontitis patients with and without diabetes. |
|
Vitamin D levels and bone mineral density: are LH levels involved in the pathogenesis of bone impairment in hypogonadal men? |
|